A microfluidic immunomagnetic bead-based system for the rapid detection of influenza infections: from purified virus particles to clinical specimens.

Seasonal and novel influenza infections have the potential to cause worldwide pandemics. In order to properly treat infected patients and to limit its spread, a rapid, accurate and automatic influenza diagnostic tool needs to be developed. This study therefore presents a new integrated microfluidic system for the rapid detection of influenza infections. It integrated a suction-type, pneumatic-driven microfluidic control module, a magnetic bead-based fluorescent immunoassay (FIA) and an end-point optical detection module. This new system can successfully distinguish between influenza A and B using a single chip test within 15 min automatically, which is faster than existing devices. By utilizing the micromixers to thoroughly wash out the sputum-like mucus, this microfluidic system could be used for the diagnosis of clinical specimens and reduced the required sample volume to 40 µL. Furthermore, the results of diagnostic assays from 86 patient specimens have demonstrated that this system has 84.8 % sensitivity and 75.0 % specificity. This developed system may provide a powerful platform for the fast screening of influenza infections.

Rapid detection of influenza A virus infection utilizing an immunomagnetic bead-based microfluidic system.

This study reports a new immunomagnetic bead-based microfluidic system for the rapid detection of influenza A virus infection by performing a simple two-step diagnostic process that includes a magnetic bead-based fluorescent immunoassay (FIA) and an end-point optical analysis. With the incorporation of monoclonal antibody (mAb)-conjugated immunomagnetic beads, target influenza A viral particles such as A/H1N1 and A/H3N2 can be specifically recognized and are bound onto the surface of the immunomagnetic beads from the specimen sample. This is followed by labeling the fluorescent signal onto the virus-bound magnetic complexes by specific developing mAb with R-phycoerythrin (PE). Finally, the optical intensity of the magnetic complexes can be analyzed immediately by the optical detection module. Significantly, the limit of detection (LOD) of this immunomagnetic bead-based microfluidic system for the detection of influenza A virus in a specimen sample is approximately 5×10(-4) hemagglutin units (HAU), which is 1024 times better than compared to conventional bench-top systems using flow cytometry. More importantly, the entire diagnostic protocol, from the purification of target viral particles to optical detection of the magnetic complexes, can be automatically completed within 15 min in this immunomagnetic bead-based microfluidic system, which is only 8.5% of the time required when compared to a manual protocol. As a whole, this microfluidic system may provide a powerful platform for the rapid diagnosis of influenza A virus infection and may be extended for diagnosis of other types of infectious diseases with a high specificity and sensitivity.

A suction-type microfluidic immunosensing chip for rapid detection of the dengue virus.

The enzyme-linked immunosorbent assay (ELISA) is widely used in medical diagnostics. In order to reduce the diagnosis time and to lower the consumption of sample/reagents in an ELISA assay, a suction-type, automatic, pneumatically-driven microfluidic chip has been designed and fabricated in this study. The microfluidic chip integrates a multi-functional micro-transport/mixing unit, for transporting metering and mixing of samples and reagents in order to automatically perform the entire ELISA protocol. A new surface modification has been adopted which allows for a high processing capacity. The detection sensitivity for the dengue virus is found to be 10(1) PFU/ml, which is much better than a conventional ELISA assay (10(3) PFU/ml). The entire assay time is only 30 min, which is much faster than with 96-well microtiter plates (4 h). The consumed sample and reagent volume is only 12 µl, which is less than a conventional assay (100 µl). The development of this microfluidic chip may be promising for other immunosensing applications.